Home
About
Overview
Sharing Data
ORCID
Help
History (1)
CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023 Aug 31; 389(9):820-832.
View in:
PubMed
subject areas
Anemia, Sickle Cell
Animals
Antigens, CD34
CRISPR-Cas Systems
Erythrocytes
Fetal Hemoglobin
Hematopoietic Stem Cell Transplantation
Hemoglobin, Sickle
Mice
Promoter Regions, Genetic
authors with profiles
Radhika R. Peddinti
James L. LaBelle